Bone marrow fat hormone may reveal chemo resistance in leukemia
NCT ID NCT07163728
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether a hormone called leptin, found in bone marrow, can predict how well chemotherapy works in adults with acute myeloid leukemia (AML). Researchers will measure leptin levels in bone marrow samples from 86 newly diagnosed patients before treatment and compare them to their response rates. The goal is to find a way to identify drug resistance early and improve treatment outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which AML patients will respond to chemotherapy, allowing for more personalized treatment plans.
- What could go wrong
- This is an early observational study with only 86 participants, so results may not apply to all patients. It does not test a new treatment, only a potential marker.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tailored chemo cocktail outsmart a common leukemia?
- What does a healthy mouth mean for people with disabilities?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can pressurized oxygen boost cord blood transplants?
- Personalized leukemia vaccine aims to outsmart relapse